Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Blocking Hyaluronic Acid Halts Progression of PH in Early Study

Hyaluronic acid, a major component of the extracellular matrix that supports cell function, directly contributes to the development of pulmonary hypertension (PH) via pulmonary vascular remodeling, a preclinical study has found. By pharmacologically blocking the production of the substance in a PH mouse model, researchers were able to prevent…

Inhaled Seralutinib Shows Promise in 2 PAH Animal Models

Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy than imatinib, an approved cancer therapy also being investigated for PAH. Gossamer Bio, seralutinib’s developer, now is testing…

High Rate of Hospitalization, Mortality With COVID-19: Study

People with pulmonary hypertension (PH) who were diagnosed with COVID-19 had a high rate of hospitalization and in-hospital mortality, a French study concluded. Risk factors for adverse outcomes included being older, male, having co-existing conditions, or comorbidities, and having more severe PH. Anticoagulants (blood thinners) were the only treatment…

Sacubitril/Valsartan Combo Found in Analysis to Improve Heart Function

Sacubitril/valsartan, a fixed-dose combination oral therapy approved for heart failure, was found to improve right heart function and lower pulmonary blood pressure, according to a new pooled analysis of multiple studies. This meta-analysis supports a new therapeutic role for sacubitril/valsartan for people with pulmonary hypertension (PH) associated with heart…

ISHLT Foundation Will Fund PH, Transplant Research Efforts

The International Society for Heart and Lung Transplantation (ISHLT) has launched the ISHLT Foundation, a new organization that will serve as ISHLT’s charitable arm to fund research grants and awards to improve patient care for advanced heart and lung diseases, including pulmonary hypertension (PH). In PH, high…

Oxygen Uptake in Exercise Test Predicts PH-LHD Outcomes: Study

Maximum oxygen uptake measured during cardiopulmonary exercise testing (CPET) independently predicted long-term survival outcomes in people with pulmonary hypertension caused by left heart disease (PH-LHD), a study reported. Further studies with a larger number of these patients are needed to confirm the findings, the researchers noted. The study, “…

Dry-powder Tyvaso Safe, Effective, More Convenient Than Nebulizer

Tyvaso DPI, an investigational dry powder formulation of the vasodilator treprostinil, was equally safe and effective, and more convenient than the approved Tyvaso (inhaled treprostinil) nebulizer for people with pulmonary arterial hypertension (PAH), final results of the BREEZE study show. These findings may facilitate Tyvaso DPI’s use earlier in…

Activating BMPR2 Protein Supported as PAH Treatment Strategy

Newly revealed biological mechanisms that underlie the development of pulmonary arterial hypertension (PAH) support activating BMPR2, the protein mutated in most familial PAH cases, as a treatment strategy, according to a study that investigated human cells and mouse models. A recent case series showed potential for the BMPR2-activator…

Oxygen Therapy Is Only Effective Treatment for COPD With PH: Study

Supplemental long-term oxygen therapy is the only effective treatment for people with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD) who have low blood oxygen, according to a systematic review of studies. Such long-term oxygen treatment “may mildly reduce severity of PH, slow PH progression over time,…

Researchers Test Prognostic Value of Breathing Reserve

Breathing reserve, a measure of lung function calculated during exercise, predicted survival in adults with congenital heart disease associated with pulmonary arterial hypertension (PAH), a study reported for the first time. Breathing reserve assessment in other diseases affecting blood vessels in the lungs also may predict survival outcomes, the…

Cardio Exercise Test May Not Be Needed to Predict PH Outcomes

A passive leg raise is equally as effective as exercise in measuring pulmonary vascular distensibility, a physiological marker to predict outcomes in people with pulmonary hypertension (PH), a study suggests. This finding is important for patients who cannot exercise or do not have access to clinical exercise facilities, the…


A Conversation With Rare Disease Advocates